对于化疗敏感、医学上适合进行自体移植的复发性弥漫大B细胞淋巴瘤(DLBCL)患者,仍应考虑进行自体移植。 对于原发难治性DLBCL或早期复发疾病、自体移植后复发或不适合自体造血干细胞移植的患者,应给予CAR-T细胞治疗。 双抗应作为CAR-T细胞治疗后的治疗,并...
Christopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.
DLBCL患者接受CAR-T治疗后,如果病情没有得到有效抑制或者复发,那么患者后续的生存期往往会比较短,而且目前没有有效的药物。双特异抗体虽然同样是通过T细胞发挥作用,但是越来越多的研究表明,在CAR-T治疗失败后,双特异抗体同样具有治疗效果,如mosunetuzumab 和odronex...
2. Geoffrey Shouse, Andy Kaempf, Max J. Gordon, et al. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023 Jul 25;7(14):3...
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission Blood. 2022 Mar 3;139(9):1330-1339. doi: 10.1182/blood.2021013289. 声明 本资讯旨在帮助医疗卫生专业人士更好地了解相...
10. Hutchings M , Avigdor A , Sureda A ,et al. Glofitamab plus polatuzumab vedotin continues to demonstrate frequent and durable responses and has a manageable safety profile in patients with ≥2L relapsed/refractory ...
经临床端综合评估,患者为原发难治性DLBCL且携带TP53突变,考虑二线治疗给予ASCT联合CAR-T细胞治疗的方案。治疗经过如下: 图1、患者二线治疗及二线维持治疗经过 影像评估 患者接受ASCT联合CAR-T细胞治疗(瑞基奥仑赛注射液)的方案治疗后12...
Real-World Data for CAR T-Cell Therapy for R/R DLBCL EP: 5.Impact of COVID-19 on CAR T-Cell Therapy for R/R DLBCL EP: 6.The Future of CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma Matthew J. Frigault, MD: There’s been a lot of talk about real-world data, how ...
近年来,嵌合抗原受体T(CAR-T)细胞疗法在治疗复发/难治性弥漫性大B细胞淋巴瘤(DLBCL)的早期临床试验中展现出令人鼓舞的疗效。然而,该疗法对原发性难治性DLBCL的治疗效果尚未得到全面评估,且其潜在的耐药机制仍有待深入探究。基于此,来...
CAR-T后格菲妥单抗 弥漫性大B细胞淋巴瘤(DLBCL)是一种侵袭性较强的B细胞非霍奇金淋巴瘤(NHL),二线治疗失败后的复发难治性(R/R)患者预后极差,中位总生存期(OS)通常不到7个月。CAR-T细胞疗法在DLBCL的二线及后续治疗中取得了突...